Index of reports
> Cases with Neoplasm Progression (9)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cabergoline where reactions include neoplasm progression. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Cabergoline side effects in 30 year old female
Reported by a health professional (non-physician/pharmacist) from Poland on 2012-07-27
Patient: 30 year old female
Reactions: Galactorrhoea, Menstrual Disorder, Prolactinoma, Drug Interaction, Neoplasm Progression
Drug(s) suspected as cause:
Cabergoline
Dosage: 0.25 mg, twice weekly
Cabergoline
Dosage: 2 mg, twice weekly
Other drugs received by patient possibly interacting with the suspect drug: Bromocriptine Mesylate
Dosage: 20 mg, daily
Bromocriptine Mesylate
Dosage: 7.5 mg, daily
Bromocriptine Mesylate
Dosage: 15 mg, daily
Oxcarbazepine
Dosage: 600 mg daily
Indication: Convulsion
Oxcarbazepine
Dosage: 1200 mg daily
Other drugs received by patient: Quinagolide; Quinagolide
Possible Cabergoline side effects in 30 year old female
Reported by a health professional (non-physician/pharmacist) from Poland on 2012-07-27
Patient: 30 year old female
Reactions: Menstrual Disorder, Galactorrhoea, Prolactinoma, Neoplasm Progression, Drug Interaction
Drug(s) suspected as cause:
Cabergoline
Dosage: 2 mg, twice weekly
Cabergoline
Dosage: 0.25 mg, twice weekly
Other drugs received by patient possibly interacting with the suspect drug: Bromocriptine Mesylate
Dosage: 15 mg, daily
Bromocriptine Mesylate
Dosage: 7.5 mg, daily
Bromocriptine Mesylate
Dosage: 20 mg, daily
Oxcarbazepine
Dosage: 600 mg daily
Indication: Convulsion
Oxcarbazepine
Dosage: 1200 mg daily
Other drugs received by patient: Quinagolide; Quinagolide
Possible Cabergoline side effects in 30 year old female
Reported by a health professional (non-physician/pharmacist) from Poland on 2012-06-26
Patient: 30 year old female
Reactions: Galactorrhoea, Menstrual Disorder, Prolactinoma, Neoplasm Progression, Drug Interaction
Drug(s) suspected as cause:
Cabergoline
Dosage: 0.25 mg, twice weekly
Cabergoline
Dosage: 2 mg, twice weekly
Other drugs received by patient possibly interacting with the suspect drug: Bromocriptine Mesylate
Dosage: 7.5 mg, daily
Bromocriptine Mesylate
Dosage: 15 mg, daily
Bromocriptine Mesylate
Dosage: 20 mg, daily
Oxcarbazepine
Dosage: 1200 mg daily
Oxcarbazepine
Dosage: 600 mg daily
Indication: Convulsion
Other drugs received by patient: Quinagolide; Quinagolide
Possible Cabergoline side effects in 30 year old female
Reported by a health professional (non-physician/pharmacist) from Poland on 2012-06-26
Patient: 30 year old female
Reactions: Menstrual Disorder, Galactorrhoea, Prolactinoma, Drug Interaction, Neoplasm Progression
Drug(s) suspected as cause:
Cabergoline
Dosage: 0.25 mg, twice weekly
Cabergoline
Dosage: 2 mg, twice weekly
Other drugs received by patient possibly interacting with the suspect drug: Bromocriptine Mesylate
Dosage: 7.5 mg, daily
Bromocriptine Mesylate
Dosage: 20 mg, daily
Bromocriptine Mesylate
Dosage: 15 mg, daily
Oxcarbazepine
Dosage: 600 mg daily
Indication: Convulsion
Oxcarbazepine
Dosage: 1200 mg daily
Other drugs received by patient: Quinagolide; Quinagolide
Possible Cabergoline side effects in 64 year old male
Reported by a physician from France on 2012-03-29
Patient: 64 year old male
Reactions: Visual Field Defect, Prolactinoma, Neoplasm Progression, Condition Aggravated
Drug(s) suspected as cause:
Cabergoline
Other drugs received by patient: Levothyroxine Sodium; Testosterone Enanthate
Possible Cabergoline side effects in 42 year old female
Reported by a health professional (non-physician/pharmacist) from Brazil on 2012-03-12
Patient: 42 year old female
Reactions: Drug Ineffective, Neoplasm Progression
Drug(s) suspected as cause:
Cabergoline
Dosage: 0.5 mg per day
Cabergoline
Dosage: 0.5 mg, 3 times a week
Indication: Adenoma Benign
Possible Cabergoline side effects in 31 year old male
Reported by a health professional (non-physician/pharmacist) from Russian Federation on 2011-11-18
Patient: 31 year old male
Reactions: Drug Ineffective, Visual Impairment, Neoplasm Progression, Headache
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cabergoline
Possible Cabergoline side effects in 50 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-10
Patient: 50 year old male
Reactions: Neoplasm Progression, Skin Hyperpigmentation, Headache, Death, Fatigue, Aspiration, Eye Movement Disorder, Back Pain, Pupillary Reflex Impaired, Dysphagia, Hyperglycaemia, Muscular Weakness, Hypoaesthesia, Hemianopia, Blood Corticotrophin Increased, Areflexia, Cortisol Free Urine Increased, Memory Impairment, Anosmia, Metastases To Bone
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cabergoline
Dosage: 0.5 mg, twice a week
Administration route: Oral
Metyrapone
Dosage: 250 mg, bid
Administration route: Oral
Octreotide Acetate
Dosage: 300 ug, tid
Octreotide Acetate
Dosage: 300 ug, tid
Indication: Blood Corticotrophin Increased
Other drugs received by patient: Rosiglitazone; Capecitabine; Cisplatin; Temozolomide; Etoposide
Possible Cabergoline side effects in 50 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-10
Patient: 50 year old male
Reactions: Neoplasm Progression, Skin Hyperpigmentation, Headache, Death, Fatigue, Aspiration, Eye Movement Disorder, Pupillary Reflex Impaired, Back Pain, Dysphagia, Hyperglycaemia, Muscular Weakness, Hypoaesthesia, Hemianopia, Blood Corticotrophin Increased, Cortisol Free Urine Increased, Areflexia, Memory Impairment, Anosmia, Metastases To Bone
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cabergoline
Dosage: 0.5 mg, twice a week
Administration route: Oral
Metyrapone
Dosage: 250 mg, bid
Administration route: Oral
Octreotide Acetate
Dosage: 300 ug, tid
Octreotide Acetate
Dosage: 300 ug, tid
Indication: Blood Corticotrophin Increased
Other drugs received by patient: Capecitabine; Temozolomide; Cisplatin; Etoposide; Rosiglitazone
|